Diligence memo · auto-generated · as of July 2, 2026

Pleopharma, Inc.

Pleopharma, Inc. looks fair against its niche peers and is active on financing cadence.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Pleopharma, Inc. operates in Pharmaceuticals, based in PHOENIXVILLE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Pleopharma, Inc. has raised $17M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $11M on 2022-05-02.

Most recent recorded round closed around 2025-06-23.

Valuation (modeled)modeled

Provath models Pleopharma, Inc. at approximately $20M (range $7.0M–$35M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.27× the median modeled value of Series A Pharmaceuticals companies in 2025–2027 (37 peers) — value vs value, same stage and era. Within the normal band (127% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 32 months.

Last raise 12 mo ago; this sector typically re-raises about every 13 months.

Raising on or ahead of the sector's normal rhythm.

The last round was 1.8× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 64% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 28% of those peers.

Closest niche peers: Incannex Healthcare Inc., Retension Pharmaceuticals, Inc., Eikonoklastes Therapeutics, Inc., Phoenicis Therapeutics, Inc., Pharmaceutical Resource Technology, Inc..

Peoplefiled

13 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.